Rybrevant and Chills - a phase IV clinical study of FDA data

Summary:

Chills is reported as a side effect among people who take Rybrevant (amivantamab-vmjw), especially for people who are male, 60+ old, have been taking the drug for < 1 month and have Non-small cell lung cancer metastatic.

The phase IV clinical study analyzes which people have Chills when taking Rybrevant. It is created by eHealthMe based on reports of 560 people who have side effects when taking Rybrevant from the FDA, and is updated regularly.

What is Rybrevant?

Rybrevant has active ingredients of amivantamab-vmjw. eHealthMe is studying from 560 Rybrevant users. Check the latest studies of Rybrevant.

What is Chills?

Chills (felling of cold) is found to be associated with 2,557 drugs and 3,473 conditions by eHealthMe. Check the latest studies of Chills.

On Aug, 02, 2026

560 people reported to have side effects when taking Rybrevant.
Among them, 13 people (2.32%) have Chills.

Among these 13 people:

How long have people been on Rybrevant when they have Chills? *

What is the gender of people who have Chills when taking Rybrevant? *

female: 36.36 %
male: 63.64 %

What is the age of people who have Chills when taking Rybrevant? *

What are other side effects people have besides Chills? *

Rashes (redness): 5 people, 38.46%
Dyspnea (difficult or laboured breathing): 5 people, 38.46%
Skin Blushing/flushing (a sudden reddening of the face, neck): 4 people, 30.77%
Infusion Related Reaction: 4 people, 30.77%
Nausea (feeling of having an urge to vomit): 3 people, 23.08%
Chest Pain: 3 people, 23.08%
Fever: 2 people, 15.38%
Arrhythmias (irregular heartbeat): 2 people, 15.38%
Urinary Tract Infection: 1 person, 7.69%
Hypotension (abnormally low blood pressure): 1 person, 7.69%

What are the existing conditions these people have? *

Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 2 people, 15.38%
Neoplasm Malignant (cancer tumour): 1 person, 7.69%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 7.69%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 7.69%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Rybrevant and have Chills?

- Check whether Chills is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rybrevant:

Rybrevant (560 reports)

Chills treatments and more:

Chills (145,628 reports)

Browse all side effects of Rybrevant:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chills:

Chills (2,558 drugs)

Browse all the conditions that are associated with Chills:

Chills (3,473 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on amivantamab-vmjw (the active ingredients of Rybrevant) and Rybrevant (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.